Amgen Inc.
Variant activin receptor
Last updated:
Abstract:
The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
Status:
Grant
Type:
Utility
Filling date:
25 Sep 2017
Issue date:
10 Sep 2019